Home LiteratureArticle Details
PMID: 19338264 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Cancer immunity ·Vol. 9 ·2009-04-02 ·Pages 3

Oble DA, Loewe R, Yu P, Mihm MC

Abstract

Tumors contain variable numbers of lymphocytes, referred to as tumor infiltrating lymphocytes (TILs). In melanoma, the intensity of this lymphocytic infiltrate is believed to correlate with outcome, though there is some debate about the applicability of this finding for all melanomas. Much research has gone into classifying TILs with respect to antigen receptor structure and the antigen to which melanoma-specific T cells react. However, these studies for the most part did not immunophenotype TILs, and recent data has revealed that the composition of tumoral lymphocytes is not homogenous, but rather represents varying contributions from many lymphocytic subsets. Furthermore, the function of TILs is often compromised as a result of the accumulation of immunoregulatory cells and various tumor escape mechanisms. These recent insights stress the need to collect more data on the composition and function of TIL infiltrates before definitive conclusions about the prognostic significance of TILs can be drawn. Advances in immunology have also facilitated the development of immunotherapeutic strategies, examples of which will be discussed with a special emphasis on blocking antibodies against CTLA-4, which are prototypical immunotherapeutic agents. This flurry of novel "biological" therapies will undoubtedly complicate our already incomplete understanding of TIL immunobiology as each of these agents has the potential to uniquely distort the series of immunological events which normally occur in untreated melanoma. Therefore, considerable research is needed to better elucidate the function and prognostic significance of TILs in both untreated melanoma and tumors treated with "biological" therapy.

MeSH Terms
Antibodies, Monoclonal/immunology,metabolism,therapeutic use Antigens, CD/immunology,metabolism CTLA-4 Antigen Cytokines/immunology,metabolism Histocompatibility Antigens Class II/immunology,metabolism Humans Immunologic Factors/immunology,metabolism Lymphocytes, Tumor-Infiltrating/immunology,metabolism Melanoma/drug therapy,immunology,metabolism Prognosis Receptors, Antigen, T-Cell/immunology,metabolism Skin Neoplasms/drug therapy,immunology,metabolism T-Lymphocyte Subsets/immunology,metabolism
Chemicals
Antibodies, Monoclonal Antigens, CD CTLA-4 Antigen CTLA4 protein, human Cytokines Histocompatibility Antigens Class II Immunologic Factors Receptors, Antigen, T-Cell
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Oble Darryl A
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Warren 827, Boston, MA 02114, USA.
Loewe Robert
Yu Ping
Mihm Martin C
References (225)
225 references, click to expand
  1. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Cancer Res. 1986 Jun;46(6):3011-7 PMID: 3486040
  2. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
    J Immunol. 2005 Oct 1;175(7):4797-805 PMID: 16177129
  3. Immunosurveillance and immunoregulation by gammadelta T cells.
    J Invest Dermatol. 2006 Jan;126(1):25-31 PMID: 16417214
  4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    J Immunother. 2006 Sep-Oct;29(5):545-57 PMID: 16971810
  5. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
    Lab Invest. 1996 Jan;74(1):43-7 PMID: 8569196
  6. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
    Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 PMID: 18287062
  7. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Cancer Res. 2005 Feb 15;65(4):1570-6 PMID: 15735047
  8. Differential expression of CTLA-4 among T cell subsets.
    Clin Exp Immunol. 2004 Jun;136(3):463-71 PMID: 15147348
  9. New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system.
    Cornea. 2000 May;19(3 Suppl):S2-6 PMID: 10832714
  10. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
    J Clin Oncol. 1999 Jul;17(7):2105-16 PMID: 10561265
  11. Cell based cancer vaccines: regulatory and commercial development.
    Vaccine. 2007 Sep 27;25 Suppl 2:B35-46 PMID: 17916462
  12. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
    Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5 PMID: 10781081
  13. T cell defined tumor antigens.
    Curr Opin Immunol. 1997 Oct;9(5):684-93 PMID: 9368778
  14. CCR4 as a novel molecular target for immunotherapy of cancer.
    Cancer Sci. 2006 Nov;97(11):1139-46 PMID: 16952304
  15. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  16. Genome-wide analysis of cancer/testis gene expression.
    Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7 PMID: 19088187
  17. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  18. Cellular and molecular characterization of the scurfy mouse mutant.
    J Immunol. 1999 Mar 1;162(5):2546-54 PMID: 10072494
  19. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
    Clin Cancer Res. 2007 Nov 1;13(21):6494-500 PMID: 17975162
  20. An essential role for Scurfin in CD4+CD25+ T regulatory cells.
    Nat Immunol. 2003 Apr;4(4):337-42 PMID: 12612581
  21. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
  22. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
    J Clin Pathol. 2006 Mar;59(3):316-24 PMID: 16505286
  23. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
    N Engl J Med. 1988 Dec 22;319(25):1676-80 PMID: 3264384
  24. GM-CSF-secreting melanoma vaccines.
    Oncogene. 2003 May 19;22(20):3188-92 PMID: 12789295
  25. Circulating gammadelta T cells in young/adult and old patients with cutaneous primary melanoma.
    Immun Ageing. 2005 Feb 01;2(1):2 PMID: 15686597
  26. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.
    Nat Genet. 2001 Jan;27(1):20-1 PMID: 11137993
  27. Cell technologies in immunotherapy of cancer.
    Adv Exp Med Biol. 2007;601:387-93 PMID: 17713028
  28. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
    J Immunother. 2005 May-Jun;28(3):258-67 PMID: 15838383
  29. Natural killer cells in human health and disease.
    Clin Immunol. 2006 Jan;118(1):1-10 PMID: 16337194
  30. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
    Clin Cancer Res. 2003 Mar;9(3):947-54 PMID: 12631591
  31. Alterations in T cell receptor and signal transduction molecules in melanoma patients.
    Clin Cancer Res. 1995 Nov;1(11):1327-35 PMID: 9815928
  32. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Clin Cancer Res. 2003 Oct 1;9(12):4404-8 PMID: 14555512
  33. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
    J Immunother. 2004 May-Jun;27(3):184-90 PMID: 15076135
  34. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.
    J Transl Med. 2005 Apr 28;3(1):17 PMID: 15860133
  35. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Cancer Res. 1988 Jan 1;48(1):206-14 PMID: 3257161
  36. MHC multimer technology: current status and future prospects.
    Curr Opin Immunol. 2005 Aug;17(4):428-33 PMID: 15967654
  37. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    J Leukoc Biol. 2006 Jun;79(6):1157-65 PMID: 16603585
  38. Analysis of two human monoclonal antibodies against melanoma.
    Int J Cancer. 1992 Dec 2;52(6):967-73 PMID: 1459738
  39. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells.
    BMC Biotechnol. 2007 Oct 18;7:70 PMID: 17945015
  40. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.
    J Clin Invest. 1998 Nov 1;102(9):1715-23 PMID: 9802885
  41. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    J Clin Oncol. 2006 Jul 1;24(19):3164-71 PMID: 16809739
  42. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Cancer Immun. 2003 Dec 10;3:17 PMID: 14664500
  43. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    J Clin Oncol. 2005 Dec 10;23(35):8968-77 PMID: 16204013
  44. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
    J Immunother. 2005 Mar-Apr;28(2):120-8 PMID: 15725955
  45. Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma.
    J Invest Dermatol. 2008 Mar;128(3):676-84 PMID: 17851585
  46. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
    Cancer. 1996 Aug 1;78(3):427-32 PMID: 8697387
  47. Expression of stress-induced MHC class I related chain molecules on human melanoma.
    J Invest Dermatol. 2002 Apr;118(4):600-5 PMID: 11918705
  48. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
    J Immunol. 2006 Nov 1;177(9):6062-71 PMID: 17056532
  49. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
    J Exp Med. 1995 Nov 1;182(5):1609-14 PMID: 7595233
  50. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.
    J Immunol. 2006 Mar 15;176(6):3301-5 PMID: 16517695
  51. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
    J Immunother. 2005 Sep-Oct;28(5):505-16 PMID: 16113607
  52. Regulatory T cells and tumor immunity.
    Cancer Immunol Immunother. 2005 Dec;54(12):1153-61 PMID: 15868167
  53. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    J Immunol. 2002 Nov 15;169(10):6036-47 PMID: 12421991
  54. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm).
    Cancer. 1985 Jul 15;56(2):413-8 PMID: 4005806
  55. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
    J Immunol. 2004 Dec 15;173(12):7125-30 PMID: 15585832
  56. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas.
    Br J Dermatol. 1999 Jan;140(1):106-8 PMID: 10215777
  57. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
    Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34 PMID: 15701862
  58. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease.
    Ann Surg. 1981 Apr;193(4):436-40 PMID: 7212806
  59. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23 PMID: 2672003
  60. Infiltrating lymphocytes in benign and malignant naevomelanocytic lesions.
    Nouv Rev Fr Hematol. 1990;32(1):9-11 PMID: 2349086
  61. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2829-33 PMID: 7511820
  62. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.
    Mol Cancer Res. 2007 Dec;5(12):1331-41 PMID: 18171991
  63. Cancer vaccines: progress reveals new complexities.
    J Clin Invest. 2002 Aug;110(3):289-94 PMID: 12163445
  64. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
    Nat Clin Pract Oncol. 2008 Sep;5(9):557-61 PMID: 18665147
  65. Melanoma immunotherapy: past, present, and future.
    Curr Pharm Des. 2005;11(27):3461-73 PMID: 16248801
  66. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
    Cancer Res. 1994 Sep 1;54(17):4734-9 PMID: 8062272
  67. Cancer vaccines: preclinical studies and novel strategies.
    Adv Cancer Res. 2006;95:115-45 PMID: 16860657
  68. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Cancer Immunol Immunother. 2000 Mar;48(12):661-72 PMID: 10752474
  69. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.
    J Invest Dermatol. 1997 Jun;108(6):914-9 PMID: 9182821
  70. Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
    Nat Rev Cancer. 2008 Apr;8(4):299-308 PMID: 18354418
  71. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.
    Cancer Res. 2006 Jul 15;66(14):7301-9 PMID: 16849580
  72. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Clin Cancer Res. 2004 Jan 15;10(2):668-80 PMID: 14760090
  73. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
    Immunity. 2002 Jul;17(1):19-29 PMID: 12150888
  74. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA.
    Cell Mol Immunol. 2005 Aug;2(4):253-8 PMID: 16274622
  75. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1.
    Nat Med. 1999 Aug;5(8):938-42 PMID: 10426319
  76. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight.
    Br J Dermatol. 2005 Jul;153(1):18-21 PMID: 16029321
  77. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  78. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
    Oncogene. 2003 May 19;22(20):3180-7 PMID: 12789294
  79. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
    Clin Cancer Res. 1998 Sep;4(9):2219-28 PMID: 9748142
  80. Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma.
    J Invest Dermatol. 2003 May;120(5):829-34 PMID: 12713589
  81. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma.
    Science. 1990 Aug 10;249(4969):672-4 PMID: 2382141
  82. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    J Immunol. 2008 Mar 1;180(5):3585-93 PMID: 18292586
  83. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
    Nat Immunol. 2003 Apr;4(4):330-6 PMID: 12612578
  84. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.
    J Immunother. 2007 Jan;30(1):123-9 PMID: 17198091
  85. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
    Immunol Rev. 2002 Oct;188:81-96 PMID: 12445283
  86. NK cells, MHC class I molecules and the missing self.
    Scand J Immunol. 2002 Mar;55(3):221-8 PMID: 11940227
  87. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7 PMID: 12682289
  88. Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma.
    Lab Invest. 1998 May;78(5):619-27 PMID: 9605186
  89. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse.
    Am J Pathol. 1991 Jun;138(6):1379-87 PMID: 2053595
  90. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
    Clin Cancer Res. 2005 Nov 1;11(21):7692-9 PMID: 16278389
  91. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 PMID: 12826605
  92. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
    J Immunol. 2005 Nov 15;175(10):7046-52 PMID: 16272366
  93. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression.
    Lab Invest. 1998 May;78(5):541-50 PMID: 9605179
  94. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
    J Exp Med. 1996 Aug 1;184(2):647-57 PMID: 8760818
  95. Regulation of the T cell response.
    Clin Exp Allergy. 2006 Nov;36(11):1357-66 PMID: 17083345
  96. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
    J Immunol. 1989 May 15;142(10):3714-25 PMID: 2785562
  97. The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.
    J Mol Med (Berl). 1998 Jan;76(1):32-47 PMID: 9462866
  98. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
    J Immunol. 2006 Aug 1;177(3):1670-8 PMID: 16849476
  99. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    J Immunother. 2005 Nov-Dec;28(6):582-92 PMID: 16224276
  100. Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules.
    J Exp Med. 1997 Oct 20;186(8):1269-75 PMID: 9334366
  101. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Ann Surg Oncol. 2005 Dec;12(12):1005-16 PMID: 16283570
  102. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
    Annu Rev Immunol. 2001;19:565-94 PMID: 11244047
  103. TCR gamma delta bearing T lymphocytes infiltrating human primary cutaneous melanomas.
    J Invest Dermatol. 1992 Mar;98(3):369-74 PMID: 1532004
  104. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
    Cancer Immunol Immunother. 2005 Nov;54(11):1072-81 PMID: 15959774
  105. Roles of cytotoxic T-lymphocyte-associated antigen-4 in the inductive phase of oral tolerance.
    Immunology. 2002 Feb;105(2):171-80 PMID: 11872092
  106. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
    Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):673-8 PMID: 16467076
  107. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
    Int Arch Allergy Immunol. 2001 Jul;125(3):256-63 PMID: 11490159
  108. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin.
    J Dermatol Sci. 2001 Jun;26(2):140-4 PMID: 11378331
  109. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.
    J Immunol. 2008 Apr 1;180(7):4606-14 PMID: 18354183
  110. Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions.
    Cancer Immunol Immunother. 1994 Oct;39(4):239-48 PMID: 7954526
  111. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
    Clin Cancer Res. 2007 Feb 1;13(3):958-64 PMID: 17289891
  112. HLA-DR antigen expression in primary melanomas of the skin.
    J Invest Dermatol. 1984 Mar;82(3):244-7 PMID: 6366074
  113. Human T cell responses against melanoma.
    Annu Rev Immunol. 2006;24:175-208 PMID: 16551247
  114. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
    Cancer Immunol Immunother. 2006 Oct;55(10):1185-97 PMID: 16468035
  115. Adoptive immunotherapy for cancer: building on success.
    Nat Rev Immunol. 2006 May;6(5):383-93 PMID: 16622476
  116. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Clin Cancer Res. 2003 Feb;9(2):606-12 PMID: 12576425
  117. Tumor antigen expression in melanoma varies according to antigen and stage.
    Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):764-71 PMID: 16467087
  118. Management of metastatic cutaneous melanoma.
    Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9 PMID: 15609471
  119. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.
    Immunol Rev. 2006 Aug;212:131-48 PMID: 16903911
  120. Inflammatory chemokines in cancer growth and progression.
    Eur J Cancer. 2006 Apr;42(6):760-7 PMID: 16510278
  121. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
    Cancer Res. 2004 Apr 15;64(8):2865-73 PMID: 15087405
  122. Current concepts of tumor-infiltrating lymphocytes in human malignancies.
    J Reprod Immunol. 2005 Oct;67(1-2):35-50 PMID: 16111767
  123. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.
    Blood. 2003 Jan 15;101(2):466-8 PMID: 12393404
  124. Innate immune recognition and suppression of tumors.
    Adv Cancer Res. 2006;95:293-322 PMID: 16860661
  125. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
    J Exp Med. 2005 Mar 7;201(5):779-91 PMID: 15753211
  126. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    J Clin Oncol. 2007 Mar 1;25(7):869-75 PMID: 17327608
  127. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  128. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    J Clin Oncol. 2000 Apr;18(8):1622-36 PMID: 10764422
  129. Tumor-induced immune dysfunction.
    Cancer Immunol Immunother. 1999 Oct;48(7):353-62 PMID: 10501847
  130. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.
    J Immunol. 1987 Feb 1;138(3):975-80 PMID: 2433337
  131. Chemokines: agents for the immunotherapy of cancer?
    Nat Rev Immunol. 2002 Mar;2(3):175-84 PMID: 11913068
  132. T-cell subsets (Th1 versus Th2).
    Ann Allergy Asthma Immunol. 2000 Jul;85(1):9-18; quiz 18, 21 PMID: 10923599
  133. Reactive oxygen species in melanoma and its therapeutic implications.
    Melanoma Res. 2007 Dec;17(6):400-9 PMID: 17992124
  134. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 PMID: 12427970
  135. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors.
    J Immunol. 2006 Oct 1;177(7):4488-94 PMID: 16982885
  136. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.
    J Immunol. 1997 Apr 15;158(8):3593-602 PMID: 9103420
  137. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
    J Immunol. 2004 Jul 15;173(2):1444-53 PMID: 15240741
  138. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.
    Am J Clin Pathol. 2002 Oct;118(4):504-11 PMID: 12375635
  139. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Cancer Invest. 2007 Sep;25(6):495-501 PMID: 17882663
  140. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Cancer Res. 2003 Jun 15;63(12):3281-8 PMID: 12810660
  141. TCR subunit specificity of CTLA-4-mediated signaling.
    J Leukoc Biol. 2003 Dec;74(6):1102-7 PMID: 12972512
  142. The central role of CD4(+) T cells in the antitumor immune response.
    J Exp Med. 1998 Dec 21;188(12):2357-68 PMID: 9858522
  143. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
    J Immunol. 2006 Jun 15;176(12):7726-35 PMID: 16751420
  144. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    J Exp Med. 1999 Dec 6;190(11):1669-78 PMID: 10587357
  145. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
    J Clin Oncol. 2001 Aug 15;19(16):3622-34 PMID: 11504744
  146. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
    J Exp Med. 1996 Aug 1;184(2):387-96 PMID: 8760792
  147. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  148. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
    Immunol Cell Biol. 2005 Aug;83(4):344-51 PMID: 16033529
  149. CD28/B7 system of T cell costimulation.
    Annu Rev Immunol. 1996;14:233-58 PMID: 8717514
  150. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
    Crit Rev Immunol. 1998;18(1-2):55-63 PMID: 9419448
  151. Cytokine-secreting tumor cell vaccines.
    Curr Opin Immunol. 2000 Oct;12(5):571-5 PMID: 11007361
  152. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Nat Med. 2002 Aug;8(8):793-800 PMID: 12091876
  153. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.
    Am J Pathol. 1987 Nov;129(2):208-16 PMID: 3499823
  154. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Clin Cancer Res. 1996 Jan;2(1):87-95 PMID: 9816095
  155. The murine antitumor immune response and its therapeutic manipulation.
    Adv Immunol. 1984;35:89-155 PMID: 6235727
  156. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Cancer. 2004 Jun 1;100(11):2281-91 PMID: 15160330
  157. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma.
    J Exp Clin Cancer Res. 1999 Jun;18(2):225-32 PMID: 10464712
  158. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.
    Pigment Cell Res. 2000;13 Suppl 8:163-9 PMID: 11041376
  159. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10.
    J Immunol. 2004 May 1;172(9):5213-21 PMID: 15100259
  160. A new member of the immunoglobulin superfamily--CTLA-4.
    Nature. 1987 Jul 16-22;328(6127):267-70 PMID: 3496540
  161. Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas.
    Virchows Arch A Pathol Anat Histopathol. 1987;410(4):355-61 PMID: 3101284
  162. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    J Clin Invest. 2006 Jul;116(7):1935-45 PMID: 16778987
  163. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease.
    J Immunol. 1989 Jan 15;142(2):471-80 PMID: 2783437
  164. The IL-2 receptor complex: its structure, function, and target genes.
    Annu Rev Immunol. 1993;11:245-68 PMID: 8476561
  165. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
    Gene Ther. 1998 Apr;5(4):481-90 PMID: 9614572
  166. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    J Clin Oncol. 2003 Sep 1;21(17):3343-50 PMID: 12947071
  167. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.
    Immunol Rev. 2001 Aug;182:18-32 PMID: 11722621
  168. CTLA-4 blockade: autoimmunity as treatment.
    J Clin Oncol. 2005 Dec 10;23(35):8926-8 PMID: 16204008
  169. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    J Immunol. 2002 Oct 1;169(7):4017-24 PMID: 12244204
  170. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
    J Immunol. 2007 Oct 1;179(7):4919-28 PMID: 17878392
  171. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
    Cancer Immunol Immunother. 2004 Aug;53(8):715-22 PMID: 14997347
  172. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.
    J Exp Med. 2001 Sep 17;194(6):847-53 PMID: 11560999
  173. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    J Immunol. 1999 Feb 1;162(3):1739-48 PMID: 9973437
  174. The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma.
    Gastric Cancer. 2002;5(4):220-7 PMID: 12491080
  175. Development and selection of gammadelta T cells.
    Immunol Rev. 2007 Feb;215:15-31 PMID: 17291276
  176. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Clin Cancer Res. 1999 Oct;5(10):2756-65 PMID: 10537339
  177. MHC antigens in human melanomas.
    Semin Cancer Biol. 1991 Feb;2(1):35-45 PMID: 1912517
  178. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
    J Immunol. 1991 May 1;146(9):3235-41 PMID: 1707934
  179. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes.
    Cytometry. 1993;14(2):196-204 PMID: 7679964
  180. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Clin Cancer Res. 2006 Dec 15;12(24):7380-8 PMID: 17189411
  181. The relatively favorable prognosis of medullary carcinoma of the breast.
    Cancer. 1949 Jul;2(4):635-42 PMID: 18144972
  182. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
    Immunogenetics. 2001 May-Jun;53(4):279-87 PMID: 11491531
  183. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Anticancer Res. 2003 Jan-Feb;23(1B):537-42 PMID: 12680142
  184. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis.
    J Immunol. 2001 Nov 1;167(9):5042-51 PMID: 11673513
  185. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  186. Class II transactivator (CIITA) isoform expression and activity in melanoma.
    Melanoma Res. 2004 Dec;14(6):453-61 PMID: 15577315
  187. The use of melanosomal proteins in the immunotherapy of melanoma.
    J Immunother. 1998 Jul;21(4):237-46 PMID: 9672845
  188. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
    J Immunol. 2002 May 1;168(9):4802-8 PMID: 11971032
  189. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis.
    Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):523-30 PMID: 716913
  190. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    J Immunol. 1996 Sep 15;157(6):2539-48 PMID: 8805655
  191. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    J Clin Oncol. 2007 Sep 1;25(25):3802-7 PMID: 17761969
  192. The histogenesis and biologic behavior of primary human malignant melanomas of the skin.
    Cancer Res. 1969 Mar;29(3):705-27 PMID: 5773814
  193. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
    J Immunother. 2006 May-Jun;29(3):284-93 PMID: 16699371
  194. CD4+ Tregs and immune control.
    J Clin Invest. 2004 Nov;114(9):1209-17 PMID: 15520849
  195. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.
    Ann Surg. 2006 Jul;244(1):113-20 PMID: 16794396
  196. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Cancer. 2006 Jun 1;106(11):2437-44 PMID: 16615096
  197. Heterogeneity of T-cell clones infiltrating primary malignant melanomas.
    J Invest Dermatol. 2006 Feb;126(2):393-8 PMID: 16374454
  198. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray.
    PLoS Med. 2005 Oct;2(10):e265 PMID: 16162034
  199. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    J Immunol. 1995 Mar 1;154(5):2257-65 PMID: 7868898
  200. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
    Dermatol Ther. 2006 Jan-Feb;19(1):9-18 PMID: 16405565
  201. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
    Semin Cancer Biol. 2007 Dec;17(6):459-68 PMID: 17768067
  202. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    J Immunol. 2002 Sep 1;169(5):2756-61 PMID: 12193750
  203. Cancer despite immunosurveillance: immunoselection and immunosubversion.
    Nat Rev Immunol. 2006 Oct;6(10):715-27 PMID: 16977338
  204. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
    J Immunol. 1999 Dec 15;163(12):6912-23 PMID: 10586094
  205. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
    Oncol Rep. 2007 Nov;18(5):1115-22 PMID: 17914561
  206. The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation.
    J Immunol. 2007 Jun 15;178(12):7710-9 PMID: 17548608
  207. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.
    Arthritis Res. 2002;4 Suppl 3:S161-7 PMID: 12110135
  208. Mechanisms of immune evasion by tumors.
    Adv Immunol. 2006;90:51-81 PMID: 16730261
  209. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
    J Exp Med. 2000 Jul 17;192(2):303-10 PMID: 10899917
  210. Molecular basis of T cell inactivation by CTLA-4.
    Science. 1998 Dec 18;282(5397):2263-6 PMID: 9856951
  211. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
    Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 PMID: 10500201
  212. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.
    Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84 PMID: 10359807
  213. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Cancer Res. 2000 Jul 1;60(13):3559-68 PMID: 10910069
  214. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
    Vaccine. 2004 Apr 16;22(13-14):1700-8 PMID: 15068853
  215. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.
    Am J Surg Pathol. 2008 Aug;32(8):1130-7 PMID: 18545145
  216. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
    J Immunother. 2004 Jan-Feb;27(1):36-47 PMID: 14676632
  217. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Cancer Res. 1989 Dec 15;49(24 Pt 1):7086-92 PMID: 2582450
  218. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C.
    J Immunol. 1989 Mar 15;142(6):1854-60 PMID: 2466079
  219. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.
    J Natl Cancer Inst. 1994 May 18;86(10):761-9 PMID: 8169974
  220. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
    Nat Med. 2003 Oct;9(10):1269-74 PMID: 14502282
  221. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
    J Immunol. 2003 Feb 15;170(4):2161-9 PMID: 12574389
  222. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.
    J Exp Med. 2004 Jun 7;199(11):1503-11 PMID: 15173207
  223. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    N Engl J Med. 2008 Jun 19;358(25):2698-703 PMID: 18565862
  224. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Cancer. 1996 Apr 1;77(7):1303-10 PMID: 8608507
  225. Fatal attraction: tumors beckon regulatory T cells.
    Nat Med. 2004 Sep;10(9):900-1 PMID: 15340410
Article Info
Journal
Cancer immunity
Abbr.
Cancer Immun
ISSN
1424-9634
Published
2009-04-02
Epub
2009-00-02
Pages
3
Language
English
Region
United States
NLM ID
101119871
PMCID
PMC2935762
Subset
IM
External Links
PubMed source PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2